Vivo Bio Tech

Why is Vivo Bio Tech Ltd. falling/rising?

As of 07-Aug, Vivo Bio Tech Ltd. is experiencing a stock price decline to 21.73, reflecting a -1.59% change and underperforming its sector. The stock has significant long-term losses, with a year-to-date drop of 31.21% and a one-year decline of 40.19%, contrasting sharply with the Sensex's performance.

As of 07-Aug, Vivo Bio Tech Ltd. is experiencing a decline in its stock price, currently at 21.73, which reflects a change of -0.35 or -1.59%. This drop follows a trend reversal after three consecutive days of gains, indicating a shift in market sentiment. The stock has underperformed its sector by 1.39% today, suggesting that it is not keeping pace with its peers.<BR><BR>In terms of longer-term performance, the stock has shown significant declines, with a year-to-date drop of 31.21% and a one-year decline of 40.19%. This is in stark contrast to the benchmark Sensex, which has only decreased by 7.89% over the same period. Additionally, over the past three years, Vivo Bio Tech Ltd. has fallen by 28.28%, while the Sensex has risen by 19.02%.<BR><BR>Despite a slight increase in investor participation, with a delivery volume rise of 9.3% against the five-day average, the stock remains lower than the 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Overall, these factors contribute to the stock's current downward movement.

Which are the latest news on Vivo Bio Tech?

Are Vivo Bio Tech Ltd. latest results good or bad?

Vivo Bio Tech Ltd.'s latest Q1 FY27 results show a 14.15% revenue growth to ₹14.28 crores, but a concerning 85.82% drop in net profit to ₹0.19 crores and declining margins indicate serious profitability issues, suggesting a challenging outlook for investors.

Vivo Bio Tech Ltd.'s latest results for Q1 FY27 present a mixed picture, but overall, the performance raises significant concerns. While the company achieved a year-on-year revenue growth of 14.15%, reaching ₹14.28 crores, this top-line growth is overshadowed by a drastic decline in profitability. The net profit plummeted by 85.82% year-on-year to just ₹0.19 crores, indicating serious issues with the company's ability to convert revenue into profit.<BR><BR>The operating margin also contracted sharply from 43.80% to 35.36%, reflecting deteriorating operational efficiency. Additionally, the PAT margin fell to a mere 1.33% from 10.71% in the same quarter last year, highlighting a severe profitability crisis.<BR><BR>The company's effective tax rate of 44.12% further complicates the situation, indicating potential tax inefficiencies that are impacting net profitability. Despite a return to profitability after a loss in the previous quarter, the recovery is weak and insufficient to inspire confidence among investors.<BR><BR>In summary, while Vivo Bio Tech has shown some revenue growth, the significant drop in net profit and margins suggests that the company's financial health is deteriorating. This combination of factors points to a challenging outlook, and investors may need to approach the stock with caution.

When is the next results date for Vivo Bio Tech Ltd.?

The next results date for Vivo Bio Tech Ltd. is 13 July 2026.

The next results date for Vivo Bio Tech Ltd. is scheduled for 13 July 2026.

How big is Vivo Bio Tech?

As of 10th June, Vivo Bio Tech Ltd. has a market capitalization of 54.00 Cr and reported Net Sales of 53.33 Cr, with a Net Profit loss of 1.70 Cr over the latest four quarters. Shareholder's Funds are valued at 77.90 Cr, and Total Assets amount to 143.23 Cr.

As of 10th June, Vivo Bio Tech Ltd. has a market capitalization of 54.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Vivo Bio Tech reported Net Sales of 53.33 Cr. However, the company experienced a loss of 1.70 Cr in Net Profit during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 77.90 Cr, while Total Assets amount to 143.23 Cr.

Who are in the management team of Vivo Bio Tech?

The management team of Vivo Bio Tech includes Kalyan Ram Mangipudi, Alangudi Sankaranarayanan, K Sunder, Hariharan Ravindran, Kunda Kalpana, Karopadi Shivanand Nayak, K Sri Kalyan, and Shyam Sunder Tipparaju in various roles such as Whole-time Directors, Chairman, and Independent Directors.

The management team of Vivo Bio Tech includes the following individuals:<BR><BR>1. Kalyan Ram Mangipudi - Whole-time Director<BR>2. Alangudi Sankaranarayanan - Whole-time Director<BR>3. K Sunder - Chairman & Independent Director<BR>4. Hariharan Ravindran - Independent Director<BR>5. Kunda Kalpana - Independent Director<BR>6. Karopadi Shivanand Nayak - Director<BR>7. K Sri Kalyan - Whole Time Director & CFO<BR>8. Shyam Sunder Tipparaju - Additional Director<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the Vivo Bio Tech?

Vivo Bio Tech's peers include Sunil Healthcare, Samrat Pharma, Biofil Chemicals, Asston Pharmaceuticals, Kabra Drugs, Shelter Pharma, Veerhealth Care, Vasundhara Rasay, and Vista Pharma. In terms of management risk, growth, and capital structure, Kabra Drugs shows the best performance, while Samrat Pharma has the lowest returns.

Peers: The peers of Vivo Bio Tech are Sunil Healthcare, Samrat Pharma, Biofil Chemicals, Asston Pharmaceu, Kabra Drugs, Shelter Pharma, Veerhealth Care, Vasundhara Rasy., and Vista Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Samrat Pharma and Vasundhara Rasy., while Average management risk is found at Asston Pharmaceu and Shelter Pharma, and the rest have Below Average management risk. Growth is Excellent at Kabra Drugs, Good at Sunil Healthcare and Shelter Pharma, Average at Veerhealth Care, and the rest have Below Average growth. Capital Structure is Excellent at Samrat Pharma and Shelter Pharma, Good at Biofil Chemicals and Veerhealth Care, Average at Asston Pharmaceu, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: Kabra Drugs has the highest 1-year return at 86.81%, while Samrat Pharma has the lowest at -41.51%. Vivo Bio Tech's 1-year return of -38.43% is better than Samrat Pharma's but worse than Kabra Drugs'. Additionally, the six-month return is negative for Sunil Healthcare, Samrat Pharma, Kabra Drugs, Vivo Bio Tech, Shelter Pharma, and Vista Pharma.

What does Vivo Bio Tech do?

Vivo Bio Tech Ltd. is a Contract Research Organization providing drug development and discovery services to the pharmaceutical and biotech sectors. As of March 2026, it reported net sales of 14 Cr and a net loss of 5 Cr, with a market cap of INR 54 Cr.

Overview:<BR>Vivo Bio Tech Ltd. is a full-service Contract Research Organization (CRO) that provides drug development and discovery services to pharmaceutical and biotech companies worldwide, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History:<BR>Vivo Bio Tech Limited was established in February 1987. The latest quarterly results reported are for March 2026, showing a net sales figure and net profit.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 14 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -5 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 54 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.72 <BR>Return on Equity: -1.86% <BR>Price to Book: 0.59 <BR><BR>Contact Details:<BR>Address: Survey #349/A Pregnapur Vlge, Gajel Telangana: 502311 <BR>Email: investors@vivobio.com <BR>Website: http://www.vivobio.com

Should I buy, sell or hold Vivo Bio Tech Ltd.?

How has been the historical performance of Vivo Bio Tech?

Vivo Bio Tech has experienced fluctuating net sales, declining from INR 55.83 crore in March 2019 to INR 46.67 crore in March 2025, but profitability improved significantly, with profit after tax rising to INR 7.28 crore in March 2025. Despite operational challenges, the company has shown an ability to increase operating profit and total assets during this period.

Answer:<BR>The historical performance of Vivo Bio Tech shows a fluctuating trend in net sales and profitability over the years, with a notable increase in profit after tax in the latest fiscal year.<BR><BR>Breakdown:<BR>Vivo Bio Tech's net sales have shown a decline from INR 55.83 crore in March 2019 to INR 46.67 crore in March 2025, with a slight increase from INR 45.45 crore in March 2024. The total operating income followed a similar trend, peaking at INR 52.23 crore in March 2023 before dropping to INR 46.67 crore in March 2025. The total expenditure, excluding depreciation, decreased from INR 42.88 crore in March 2020 to INR 26.16 crore in March 2025, contributing to an increase in operating profit, which rose from INR 12.47 crore in March 2020 to INR 25.31 crore in March 2025. Profit before tax also saw a significant rise, reaching INR 8.79 crore in March 2025, up from INR 4.06 crore in March 2024. Consequently, profit after tax surged to INR 7.28 crore in March 2025, compared to INR 2.53 crore in March 2024. The company's total assets increased from INR 62.14 crore in March 2020 to INR 143.23 crore in March 2025, while total liabilities also rose from INR 62.14 crore to INR 46.29 crore during the same period. Cash flow from operating activities decreased to INR 11 crore in March 2025, down from INR 15 crore in March 2024, while cash flow from investing activities turned negative at INR -15 crore. Overall, Vivo Bio Tech has demonstrated a capacity for profitability despite fluctuations in sales and operational challenges.

Is Vivo Bio Tech overvalued or undervalued?

As of May 26, 2025, Vivo Bio Tech is considered very attractive and undervalued with a PE ratio of 9.33, an EV to EBITDA ratio of 5.88, and a PEG ratio of 0.07, significantly lower than its peers like Sun Pharma and Divi's Lab, despite underperforming the Sensex over the past year.

As of 26 May 2025, the valuation grade for Vivo Bio Tech has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 9.33, an EV to EBITDA ratio of 5.88, and a PEG ratio of 0.07, all of which suggest that the stock is trading at a significant discount compared to its earnings growth potential.<BR><BR>In comparison to its peers, Vivo Bio Tech stands out with a much lower PE ratio than Sun Pharma (35.25) and Divi's Lab (79.33), both of which are categorized as expensive. Additionally, its EV to EBITDA ratio is significantly better than those of its peers, reinforcing the undervaluation narrative. While Vivo Bio Tech has underperformed the Sensex over the past year with a return of -5.27% compared to the Sensex's 7.60%, its strong valuation metrics suggest that it may present a compelling investment opportunity moving forward.

What is the technical trend for Vivo Bio Tech?

As of May 12, 2025, the trend is mildly bearish due to daily moving averages and monthly bearish indicators, despite some mildly bullish signals on the weekly charts, with the stock underperforming against the Sensex over the past few years.

As of 12 May 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating a mildly bearish trend, while the monthly MACD and RSI are both bearish. The weekly MACD and KST show mildly bullish signals, but the overall sentiment remains cautious due to the bearish indicators on the monthly Bollinger Bands and the lack of a clear trend in Dow Theory. The stock has underperformed against the Sensex over the past year and three years, further supporting the bearish outlook.

Who are the top shareholders of the Vivo Bio Tech?

The top shareholders of Vivo Bio Tech are Cryptologic Systems Private Limited with 7.5% and Elite Class Asset Holdings Ltd with 7.25%. Individual investors hold a combined 35.48%, and there are no mutual funds or foreign institutional investors involved.

The top shareholders of Vivo Bio Tech include Cryptologic Systems Private Limited, which holds the highest promoter stake at 7.5%. Following closely is Elite Class Asset Holdings Ltd, the highest public shareholder, with a holding of 7.25%. Additionally, individual investors collectively hold 35.48% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

Has Vivo Bio Tech declared dividend?

No Dividend History Available